相关临床试验
1192
602 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1956
招募中
264
22.1%
暂停
2
0.2%
撤回
1
0.1%
进行中（未招募）
50
4.2%
Unknown
2
0.2%
已完成
317
26.6%
尚未招募
552
46.3%
暂无批准数据
- A six-year retrospective study at an AIIMS tertiary care hospital found that TORCH pathogens remain a serious risk for congenital infections in North India, even as rubella vaccination rates improve. - Cytomegalovirus (CMV) exposure remained consistently high throughout the 2019–2025 study period, underscoring the virus's wide community circulation and the need for greater awareness. - While rubella immunity was high due to vaccination, a significant minority of patients remained susceptible to both rubella and toxoplasmosis, which is preventable through hygiene measures. - Researchers caution that a "one-size-fits-all" approach to TORCH testing is insufficient and call for pathogen-specific prevention strategies, including public health education on food safety and prenatal care.
- The largest study to date testing leucovorin for autism traits has been retracted by the European Journal of Pediatrics due to data inconsistencies and statistical errors that could not be replicated. - The retraction removes significant evidence supporting leucovorin use in autism, leaving researchers with limited and inconsistent data as the FDA considers expanding the drug's approval for cerebral folate deficiency. - A new 80-child trial led by Richard Frye is expected to provide clearer evidence by early 2026, representing the most robust test of leucovorin's effectiveness in autistic children to date.
- The Defence Research and Development Organisation (DRDO) and AIIMS-Rishikesh have signed a memorandum of understanding to conduct clinical trials and advanced research in biomedical devices for extreme environments. - The collaboration between DRDO's Defence Institute of Physiology and Allied Sciences (DIPAS) and AIIMS-Rishikesh aims to develop products, technologies, and strategies to mitigate adverse effects of extreme environments on human performance. - The partnership will focus on formulating biomedical devices and supplements specifically designed to enhance human performance in challenging environmental conditions.
• Indigenously developed HPV test kits for cervical cancer screening were launched in Delhi, targeting the seven to eight most common cancer-causing HPV types specific to India's population. • The RTPCR-based diagnostic kits, validated through collaborative research led by AIIMS Delhi, offer a cost-effective alternative to traditional Pap smears and HPV DNA tests for national cancer screening programs. • With cervical cancer being the second most common cancer among Indian women and accounting for 25% of global mortality, these kits align with WHO's recommendation for HPV testing as the preferred screening method.
- The phase 3 ACCELERATE trial found that adding chemoradiation (CRT) to chemotherapy did not improve relapse-free survival (RFS) in patients with resected gallbladder cancer. - Median survival was 52.7 months, with a hazard ratio of 1.59 for RFS in the combination arm compared to chemotherapy alone. - The trial, though the first prospective study on adjuvant CRT in gallbladder cancer, requires a larger sample size to validate these findings due to incomplete accrual.
- Early, intensive 'top-down' therapy with TNF blockers plus immunomodulators shows superior outcomes compared to the traditional 'step-up' approach for newly diagnosed Crohn's disease. - Risankizumab (Skyrizi) and guselkumab (Tremfya) receive FDA approval for ulcerative colitis, offering new options for patients who have not responded well to conventional treatments. - Research indicates intensified infliximab dosing does not improve outcomes in steroid-refractory acute severe ulcerative colitis, suggesting a need for alternative strategies. - Long-term data reveals tulisokibart maintains clinical and endoscopic improvements in IBD patients, supporting its advancement to phase III trials.
